603590.SHG Beijing Konruns Pharmaceutical Co Ltd
- Market cap
- CNY 4.13B
- P/E
- 29.8x
- P/B
- 1.24x
- ROE
- 4.2%
- Dividend yield
- 2.48%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603590.SHG undervalued?
Graham number603590.SHG trades 28.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Konruns Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Beijing Konruns Pharmaceutical Co Ltd yet.
Beijing Konruns Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the t…
Full company profileBeijing Konruns Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Konruns Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 346M | 591M | 973M | 1.07B | 809M | 810M | 867M | 920M | 825M | 915M | 854M |
| Gross Profit | 308M | 546M | 923M | 1.01B | 749M | 704M | 740M | 819M | 739M | 823M | 766M |
| Operating Income | 208M | 557M | 300M | 300M | 210M | 192M | 141M | 143M | 39.1M | 199M | 160M |
| EBITDA | 188M | 207M | 204M | 240M | 142M | 144M | 152M | 165M | 147M | 233M | 175M |
| Net Income | 192M | 479M | 264M | 266M | 183M | 148M | 101M | 150M | 42.2M | 166M | 133M |
| EPS | 1.60 | 3.99 | 1.98 | 1.66 | 1.15 | 0.94 | 0.65 | 0.96 | 0.27 | 1.04 | 0.83 |
| Balance Sheet | |||||||||||
| Total Assets | 1.02B | 1.67B | 2.92B | 3.17B | 3.79B | 3.37B | 3.42B | 3.78B | 3.92B | 4.09B | 4.11B |
| Total Liabilities | 147M | 319M | 439M | 446M | 702M | 241M | 235M | 418M | 494M | 599M | 632M |
| Shareholders' Equity | 875M | 1.36B | 2.48B | 2.73B | 3.08B | 2.89B | 2.93B | 3.06B | 3.14B | 3.21B | 3.19B |
| Cash & Short-term Investments | 214M | 543M | 1.69B | 1.80B | 1.53B | 608M | 626M | 627M | 641M | 333M | 429M |
| Total Debt | - | - | - | - | 24.5M | 18.6M | 12.4M | 141M | 202M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 148M | 270M | 263M | 262M | 58.4M | 70.9M | 120M | 199M | 172M | 116M | - |
| Capital Expenditure | 179M | 33.7M | 16.8M | 18.9M | 50.4M | 165M | 96.3M | 101M | 104M | 53.4M | 87.3M |
| Free Cash Flow | -30.4M | 237M | 246M | 243M | 8.03M | -93.7M | 23.4M | 98.4M | 68.2M | 62.2M | -33.1M |
| Ratios | |||||||||||
| ROE | 21.9% | 35.3% | 10.6% | 9.8% | 6.0% | 5.1% | 3.5% | 4.9% | 1.3% | 5.2% | 4.2% |
| ROA | 18.7% | 28.6% | 9.0% | 8.4% | 4.8% | 4.4% | 3.0% | 4.0% | 1.1% | 4.1% | 3.2% |
| Net Profit Margin | 55.4% | 81.1% | 27.1% | 25.0% | 22.7% | 18.3% | 11.7% | 16.4% | 5.1% | 18.1% | 15.6% |
| Debt to Equity | - | - | - | - | 0.01x | 0.01x | 0.00x | 0.05x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Konruns Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.48%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 61.7%
- Ex-dividend date
- Jul 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 102M | 0.64 | 61.7% |
| 2024 | CNY 53.5M | 0.34 | 126.7% |
| 2023 | CNY 34.9M | 0.22 | 23.2% |
| 2022 | CNY 46.9M | 0.30 | 46.3% |
| 2021 | CNY 55.2M | 0.35 | 37.3% |
| 2020 | CNY 80.0M | 0.50 | 43.6% |
| 2019 | CNY 80.0M | 0.50 | 30.1% |
| 2018 | CNY 80.0M | 0.60 | 30.3% |
| 2017 | CNY 80.0M | 0.67 | 16.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Beijing Konruns Pharmaceutical Co Ltd
- Insiders 49.66%
- Institutions 4.18%
- Public & others 46.16%
- Shares outstanding 161M
- Free float 81.4M
Beijing Konruns Pharmaceutical Co Ltd company profile
- Company name
- Beijing Konruns Pharmaceutical Co Ltd
- Ticker
- 603590.SHG
- ISIN
- CNE1000036K3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 793
- Fiscal year end
- December
- Address
- Building 3, No. 7 Science Park Road, Beijing, China, 102206
- Phone
- 86 10 8289 8898
- Website
- konruns.cn
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.
Beijing Konruns Pharmaceutical Co Ltd management
4- Mr. Zhanqi NiuPresident & Director · born 1967
- Mr. Xiaohan LiuCFO & Director · born 1988
- Mr. Xiao Dong HuangSecretary to the Board · born 1971
- Jing WangAccounting Supervisor